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Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors (NRs) that regulate genes involved in lipid and glucose
metabolism. PPAR activity is regulated by interactions with cofactors and of interest are cofactors with ubiquitin ligase activity.
The E6-associated protein (E6-AP) is an E3 ubiquitin ligase that aﬀects the activity of other NRs, although its eﬀects on PPARs
have not been examined. E6-AP inhibited the ligand-independent transcriptional activity of PPARα and PPARβ, with marginal
eﬀects on PPARγ, and decreased basal mRNA levels of PPARα target genes. Inhibition of PPARα activity required the ubiquitin
ligase function of E6-AP, but occurred in a proteasome-independent manner. PPARα interacted with E6-AP, and in mice treated
with PPARα agonist cloﬁbrate, mRNA and protein levels of E6-AP were increased in wildtype, but not in PPARα null mice,
indicating a PPARα-dependent regulation. These studies suggest coordinate regulation of E6-AP and PPARα, and contribute to
our understanding of the role of PPARs in cellular metabolism.
Copyright © 2008 Lakshmi Gopinathan et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
The peroxisome proliferator activated receptors (PPARs)
are nuclear hormone receptors that regulate lipid and
glucose metabolism, and are critical to the maintenance of
cellularenergyhomeostasis.Inaddition,theyregulateseveral
b i o l o g i c a lp r o c e s s e ss u c ha si n ﬂ a m m a t i o n ,d i ﬀerentiation,
apoptosis,andwoundhealing[1,2].Threediﬀerentsubtypes
of PPARs mediate these responses: PPARα,P P A R β,a n d
PPARγ.P P A R α is activated by fatty acids, fatty acid metabo-
lites, and peroxisome proliferators, a diverse group of xeno-
biotics that includes the ﬁbrate hypolidemic drugs, phthalate
esters, and herbicides [3]. Regulation of gene expression by
PPARα follows the classical ligand-dependent transcription
factor mechanism. Upon ligand binding, PPARα binds to
PPAR-response elements (PPREs) in the promoter of target
genes as a heterodimer with retinoid X receptor (RXR).
The multiple protein-PPARα interactions that occur in the
transcription complex are important for proper target gene
regulation [4]. These proteins, often called coregulators, can
increase (coactivators) or repress (corepressors) transcrip-
tional activity. Some coregulators possess enzymatic activity
such as histone acetyl transferase or histone deacetylase, and
modulate chromatin structure to regulate gene transcription
[5]. Several proteins with ubiquitin ligase activity have been
characterized in the last few years as coregulators for nuclear
receptors. The recruitment of ubiquitin-proteasome com-
ponents to the promoters of nuclear receptor target genes
suggest an additional layer of transcriptional regulation by
the ubiquitin-proteasome pathway [6–8].
This study examines regulation of PPARα by E6-
associatedprotein(E6-AP),aproteinlinkedtotheAngelman
syndrome and an E3 ubiquitin ligase that belongs to the
HECT (homologous to the E6-AP C-terminus) family [9].
AblationofE6-APinmiceisassociatedwithsteroidhormone
resistance and reproductive defects [10]. E6-AP coactivates
nuclear receptors such as the estrogen receptor (ER) and
the progesterone receptor [11]. In addition, it mediates
proteasomal degradation of proteins such as the nuclear
receptor coactivator AIB1 [12], and tumor suppressors Rb2 PPAR Research
(retinoblastoma protein), and p53 [13–15]. The studies
presented here suggest a role for the ubiquitin ligase function
of E6-AP in regulating PPARα activity.
2. MATERIALS AND METHODS
2.1. Plasmids
The plasmids pBKRSV-E6AP, pBKRSV-E6AP-C833S, and
pM-E6AP were a kind gift from Dr. Zafar Nawaz (Depart-
ment of Cell Biology, Baylor College of Medicine, Hous-
ton, Tex, USA). The construction of the pVP16-PPARα
plasmid has been described previously [16]. The pFR-
luciferase (UAS luciferase) plasmid was purchased from
BD Biosciences Clontech (Palo Alto, Calif, USA), while
pRL/TK and pRL/CMV were from Promega (Madison,
Wis, USA). The peroxisome proliferator response element
(PPRE) reporter pACO (-581/-471) G.Luc was supplied by
Dr. Jonathan Tugwood (AstraZeneca Maccelsﬁeld, UK) and
has been described previously [17]. The pcDNA3.1/V5-His-
PPARα plasmid has been described previously [16]. The
pcDNA3.1/FLAG-PPARβ and pcDNA3.1-PPARγ plasmids
were a kind gift from Dr. Curtis Omiecinski (Department of
Veterinary and Biomedical Sciences, The Pennsylvania State
University, Pa, USA).
2.2. Transfectionsandreporterassays
FaO cells (maintained in DMEM/Nutrient F-12 Ham with
8%serumand100units eachofpenicillinandstreptomycin)
were transfected using Lipofectamine RNAiMAX reagent
(Invitrogen, Carlsbad, Calif, USA), following manufacturer’s
instructions. Lipofectamine (Invitrogen) was used to trans-
fect 293T cells (maintained in HG-DMEM with 8% serum
and 100 units each of penicillin and streptomycin) according
to the manufacturer’s instructions. For reporter assays
examining transient PPRE activity, all transfections included
pRL/CMV (Promega) to control for transfection eﬃciency
and ACO-luciferase. When indicated, following transfection,
cells were treated with 0.1% DMSO or 5μM MG132 for 6
hours.ForreporterassaysexaminingtransientGal4response
element activity, all transfections included pRL/CMV to
control for transfection eﬃciency and pFR-Luciferase. In
Gal4 response element assays, cells were treated for 6 hours
with 0.1% DMSO or 50μM Wy-14,643 before lysis. Cells
were lysed and renilla and ﬁreﬂy luciferase activities were
examined using the Dual Luciferase Assay kit (Promega).
Luciferase activity was corrected for transfection eﬃciency
(pRLTK/pRLCMV) and extraction yield (via total protein
assay).
2.3. Real-timePCR
Total RNA was isolated using Tri Reagent (Sigma, St. Louis,
Mo, USA) according to the manufacturer’s protocol. The
total RNA was reverse transcribed using the ABI High
CapacitycDNAArchiveKit(AppliedBiosystems,FosterCity,
Calif,USA).Standardcurvesweremadeusingserialdilutions
from pooled cDNA samples. Real Time PCR was performed
using the SYBR Green PCR Mater Mix (Applied Biosystems)
according to the manufacturer’s protocol and ampliﬁed on
the ABI Prism 7300 Sequence Detection system. Messenger
R N Al e v e l so fa l lg e n e sw e r en o r m a l i z e dt oβ-actin mRNA.
Primer sequences (5 -3 ) are E6-AP forward: gaaatgaggcct-
gcacgaat, E6-AP reverse: gaagaaaagttggacaggaagca, β-actin
forward: ggctctatcctggcctcactg, β-actin reverse: cttgctgatcca-
catctgctg. Primers for Acyl CoA Oxidase (ACO) Cytochrome
P450 IV A10 (CYP4A10), Angiopoietin-like protein 4
(Angplt4), have been described previously [16]. Sequences
(5 -3 ) for other genes measured are fatty acid binding
protein 1 (FABP1) forward: ttctccggcaagtaccaagtg, FABP1
reverse: tcatgaagggctcaaagttctctt, Enoyl CoA Hydratase for-
ward: cccgcaggatctttaacaagc, Enoyl CoA Hydratase reverse:
cactgtccatgttgggcaag.
2.4. Westernblotting
M o u s el i v e r sw e r eh o m o g e n i z e di nl y s i sb u ﬀer containing
50mM Tris (pH 8), 120mM NaCl, 0.5% Nonidet P-40,
and 1 : 100 dilution of protease-inhibitor cocktail (Sigma)
after which particulates were removed by centrifugation.
Liver lysates were subjected to SDS/PAGE. Proteins were
transferred to Immobilon-PVDF membrane (Millipore),
followedbywesternusinganti-E6APantibody(H-182,Santa
Cruz Biotechnology). Band intensities were quantitated
using Optiquant Acquisition and Analysis Software.
2.5. Mice
8-week old-male wild-type, and PPARα- n u l lm i c e[ 18]w e r e
housed in a light (12 hours light/12 hours dark) and
temperature(25
◦C)controlledenvironmentinmicroisolator
cages. Mice were gavaged daily with either vehicle control
(corn oil) or 500mg cloﬁbrate/kg body weight for 14 days.
Mice were euthanized, livers weighed and homogenized,
RNA or protein isolated for analysis as described above.
3. RESULTS
3.1. E6-APinhibitsthetranscriptionalactivityof
PPARα,PP ARβ,andPPARγ
The transcriptional activity of PPARα,P P A R β/δ,a n dP P A R γ
isotypes was examined in the presence of E6-AP, by mea-
suring the activity of a reporter gene under the control of
a natural PPRE. As seen in Figure 1, transfecting increasing
amounts of E6-AP inhibited PPAR transactivation in a dose-
dependent manner for all three PPAR isotypes. A 40%
decrease in transactivation was observed for PPARα and
PPARβ, with a statistically signiﬁcant decrease observed ﬁrst
at a ratio of 1.5 : 1 for E6-AP : PPARα,a n d2:1f o rE 6 -
A P:P P A R β. A 30% decrease in transactivation was seen
with PPARγ, with a statistically signiﬁcant decrease observed
ﬁ r s ta tar a t i oo f3:1f o rE 6 - A P:P P A R γ.N oc h a n g e sw e r e
observed in ligand-induced activity of the receptors in the
presence of E6-AP (data not shown).Lakshmi Gopinathan et al. 3
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Figure 1: E6-AP inhibits the transcriptional activity of PPARα,
PPARβ,a n dP P A R γ. 293T cells were transfected with plas-
mids expressing 4X-ACO-Luciferase, pRLCMV, PPARα,P P A R β or
PPARγ, and E6-AP. Cells were lysed and luciferase activity was
corrected for transfection eﬃciency and protein. Asterisks indicate
a signiﬁcant diﬀerence in luciferase values when compared to the 0
ratio group. (∗P<. 05 with statistical analysis using ANOVA). The
graphs are representative of 3 independent experiments.
3.2. E6-APoverexpressionaffectsPPARαtargetgenes
To furtherexamine theeﬀectofE6-AP onthetranscriptional
activity of PPARα, E6-AP was expressed in FaO cells by
transient transfection, followed by treatment with PPARα
ligand Wy-14,643. The eﬀect of E6-AP overexpression on
mRNA levels of endogenous PPARα target genes was mea-
sured. The genes examined (angiopoietin-like protein 4 or
Angplt4, fatty acid binding protein 1 or FABP1, acyl CoA
oxidase or ACO and enoyl CoA hydratase) were chosen
based on their role in PPARα-mediated lipid metabolism,
or were previously identiﬁed in gene expression microarrays
in FaO cells [19]. As seen in Figure 2, E6-AP expression
resulted in statistically signiﬁcant changes in mRNA levels
Angplt4 (24% decrease) and FABP1 (28% decrease), in the
absence of ligand. As previously seen with PPRE-driven
reporter assays (Figure 1), no changes were seen in ligand-
induced mRNA levels of PPARα target genes with E6AP
expression.
3.3. E6-APinteractswithPPARα
To examine if the eﬀect of E6-AP on the transcriptional
activity of PPARα was due to a direct interaction between
the two proteins, mammalian-two-hybrid assays were per-
formedusingplasmidsexpressingPPARαfusedtothepVP16
activation domain and E6-AP in the pM vector. The Gal4
responseelementreporter(pFR-luciferase)wasusedtoassess
the interaction between E6-AP and PPARα.A ss e e ni n
Figure 3, induction with PPARα agonist Wy-14,643 was seen
only when E6-AP was coexpressed with PPARα, indicating
an interaction between the two proteins.
3.4. TheE3ubiquitinligasefunctionof
E6-APisrequiredforinhibitionof
PPARαtranscriptionalactivity
InordertodetermineiftheeﬀectofE6-APonPPARαactivity
was mediated by the E3 ubiquitin ligase function of E6-
AP, E6-AP C833S, a mutant defective in ubiquitin ligase
function was used. Unlike the changes in reporter activity
seen with wildtype (WT) E6-AP (Figure 1), transfecting
increasing amounts of E6-AP-C833S did not result in
any changes in activity (Figure 4(a)), indicating that the
ubiquitin ligase function of E6-AP is required for regulating
the transcriptional activity of PPARα. These diﬀerences were
not due to diﬀerent transfection eﬃciencies, since both E6-
AP WT and E6-AP-C833S expressed equally well in these
cells (data not shown). To further assess if E6-AP-mediated
inhibition of PPARα transactivation was via proteasomal
degradation, PPRE-dependent reporter assay was performed
in the presence of proteasome inhibitor MG132. Trans-
fecting increasing amounts of E6-AP resulted in decreased
reporter activity in the presence and absence of MG132
(Figure 4(b)), indicating that E6-AP-mediated inhibition of
PPARαtransactivationoccursviaaproteasome-independent
mechanism.4 PPAR Research
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Figure 2:E6-APexpressionresultsindecreasedmRNAlevelsofPPARαtargetgenes.FaOcellsweretransfectedwithemptyvectororplasmid
expressing E6-AP, followed by treatment with 0.1% DMSO or 50μM Wy-14,643 for 6 hours. Total RNA was isolated from the cells and real-
timePCRwasperformedonreversetranscribedRNA.Asterisksindicateasigniﬁcantdiﬀerencewhencomparedtothecorrespondingcontrol
group. (∗P<. 05 with statistical analysis using ANOVA). The graphs represent mean values obtained from 2 independent experiments.Lakshmi Gopinathan et al. 5
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Figure 3: E6-AP interacts with PPARα. 293T cells were transfected
withplasmidsexpressingpFR-Luciferase,pRLCMV,pVP16-PPARα,
pM-E6-AP. Cells were lysed and luciferase activity was corrected
for transfection eﬃciency and protein. Asterisks indicate a signif-
icant diﬀerence in Wy-14,643 induction when compared to the
corresponding DMSO group. (∗P<. 05 with statistical analysis
using ANOVA). The graph is representative of 2 independent
experiments.
3.5. E6-APisregulatedinvivoin
aPP ARα-dependentmanner
Since NR-mediated transcriptional regulation of E3 ligases
has been demonstrated in a few studies [20–22], regulation
of E6-AP in response to PPARα ligand was examined in
vivo. Wild type and PPARα null mice were maintained on
a cloﬁbrate or control diet for two weeks, following which
their livers were analyzed for mRNA and protein levels of
E6-AP. As expected, mRNA levels of known PPARα target
genes (acyl CoA oxidase or ACO and cytochrome P450 IV
A10 or CYP4A10) were induced in response to cloﬁbrate and
thisr espo nsewasd e f ecti v einPP ARαnull mice (Figure 5(a)).
E6-AP mRNA (Figure 5(a)) and protein (Figure 5(b)) levels
were signiﬁcantly increased in wildtype mice in response to
cloﬁbrate, but not in PPARα null mice, indicating a PPARα-
dependent regulation.
4. DISCUSSION
The regulation of PPARs by the ubiquitination has been
the subject of limited investigation. However, recent stud-
ies suggest ligand-mediated regulation of PPARs via the
ubiquitin-proteasome system, although no ubiquitin ligase
has been identiﬁed. PPARα and PPARβ ligands aﬀect
receptor ubiquitination and protein levels [23–26]. Ligand
binding induces transcriptional activation of PPARγ that
is followed by degradation [27]. This study identiﬁes the
E3 ubiquitin ligase E6-AP, as regulator of PPAR activity.
The transcriptional activity of all three PPAR isotypes was
inhibited by E6-AP. No changes were observed in ligand-
induced transcriptional activity in the presence of E6-AP.
PPARα and E6-AP interacted in mammalian two hybrid
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Figure 4: E3 ubiquitin ligase activity of E6-AP is required for
regulating PPARα transactivation. (a) 293T cells were transfected
with plasmids expressing 4X-ACO-Luciferase, pRLCMV, PPARα,
E6-AP, or E6-AP-C833S that is defective in ubiquitin ligase
function. (b) Cells were treated with 0.1% DMSO or 5μM MG132
for6hours.Cellswerelysedandluciferaseactivitywascorrectedfor
transfection eﬃciency and protein. Asterisks indicate a signiﬁcant
diﬀerence when compared to the corresponding 0 ratio group.
(∗P<. 05 with statistical analysis using ANOVA). The graph is
representative of 3 independent experiments.
assays, and by using an E6-AP mutant defective in ubiquitin
ligase activity, we demonstrate that inhibition of PPARα
activity required the E3 ubiquitin ligase function of E6-AP.
Interestingly, the presence of proteasome inhibitor MG132
had no eﬀect on inhibition of PPARα transactivation,
suggesting that the proteasomal degradation is not required
for E6-AP-mediated regulation of receptor transcriptional
activity. This ﬁnding points to nonproteolytic functions of
ubiquitination in modulating PPARα activity. The multi-
faceted roles of ubiquitin in regulating protein localization,
recruiting coregulators, and modifying chromatin structure
are now well-recognized [7, 8, 28]. It would be of interest to6 PPAR Research
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Figure 5: E6-AP is induced by cloﬁbrate in a PPARα-dependent manner. Wildtype and PPARα null mice were treated with control vehicle
or cloﬁbrate for 2 weeks. Groups of ﬁve mice were used for each treatment. (a) Total RNA was isolated from liver and mRNA levels were
measured using real-time PCR. (b) Protein isolated from liver was analyzed for E6AP expression by western blot. The graph (lower panel)
depicts mean (n = 5) band intensity. Asterisks indicate a signiﬁcant increase in cloﬁbrate induction when compared to the PPARα null
group. (∗P<. 05 with statistical analysis using ANOVA).
examine these possibilities in regulation of PPARα function
by E6-AP.
The inhibition of PPARα transcriptional activity by E6-
AP is in contrast to previous ﬁndings with the progesterone
receptor,whereE6-APcoactivatedreceptorfunction,andthe
ubiquitin ligase activity was dispensable for its coactivating
ability [11]. These observations suggest diﬀerent mecha-
nisms of E6-AP-mediated regulation of nuclear receptors.
E6-AP is recruited to the ER-responsive pS2 promoter and
is preferentially associated with E2-liganded ERα [29]. It
would be of interest to determine if E6-AP is recruited
to promoters of PPARα target genes, as a mechanism ofLakshmi Gopinathan et al. 7
transcriptional regulation. Evidence also exists for NR-
mediated transcriptional regulation of E3 ligases. Estrogen
activation of ERα induces the expression of two ubiquitin
ligases, MDM2 and Siah2 [20–22]. MDM2 is also regulated
by the thyroid hormone receptor [30]o r p h a nr e c e p t o rT R 3
[31], and constitutive androstane receptor (CAR) [32]. The
breast cancer associated gene (BCA2) was identiﬁed as an E3
ubiquitinligaseandBCA2expressioncorrelateswithpositive
ER status in breast tumors, suggesting that BCA2 and ER
might be coregulated [21]. Our study shows that E6-AP
mRNA and protein levels are increased in mice in response
to PPARα ligand cloﬁbrate in wildtype but not PPARα null
mice, indicating a coordinate mode of regulation between
PPARα and E6-AP. In contrast to the ligand-independent
decreaseinPPARαtranscriptionalactivitymediatedbyE6AP
in FaO cells, ligand treatment resulted in an increase in E6-
AP expression in mice that was PPARα-dependent. These
results allude to the existence of a feedback loop between
PPARα and E6-AP wherein PPARα increases the expression
of a negative regulator for control of its transcriptional
activity.
Studies in our laboratory have identiﬁed MDM2 as
another ubiquitin ligase for PPARα (unpublished results).
MDM2 regulated the transcriptional activity of PPARα by
being recruited to the promoters of PPARα target genes in
response to ligand, and it interacted with the A/B domain
of PPARα. The various biological processes regulated by
PPARs are crucial in control of disorders such as diabetes,
inﬂammation, and cardiovascular ailments, and ubiquitin
ligases such as E6-AP and MDM2 may present useful targets
for pharmacological intervention and improved PPAR-based
therapeutics.
In addition to contributing to understanding PPAR
regulation by ubiquitination, other interesting connections
can be made about the signiﬁcance of the E6-AP-PPARα
interaction. E6-AP mediates ubiquitination and degradation
of the Hepatitis C virus (HCV) core protein, which plays a
crucialroleinHCV-relatedliverdisease[33].HCVinfections
are associated with reduced hepatic PPARα expression [34–
37], and PPARα is implicated in HCV core protein-mediated
hepatic steatosis and dysregulated lipid metabolism [37].
The regulation of PPARα by E6-AP may provide a basis for
HCV-induced progression of liver disease, and is worthy of
investigation.
5. CONCLUSIONS
This study identiﬁes E6-AP, an E3 ubiquitin ligase,
as a PPARα-interacting protein that inhibited ligand-
independent PPARα transactivation and decreased the basal
mRNA levels of PPARα target genes. The E3 ubiquitin ligase
function of E6AP was required for inhibition of PPARα
transcriptional activity, and this inhibition occurred in a
proteasome-independent manner. E6-AP was induced in
vivo in response to PPARα ligand, and was regulated in a
PPARα-dependent manner. A better understanding of the
role of E6-AP and other ubiquitin ligases in the regulation
of PPARs could help improve treatment strategies against
metabolic diseases.
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